10q10k10q10k.net
STANDARD BIOTOOLS INC.

STANDARD BIOTOOLS INC.LABEarnings & Financial Report

Nasdaq

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

NextMar 11, 2026

LAB Q3 2025 Key Financial Metrics

Revenue

$19.6M

Gross Profit

$9.5M

Operating Profit

$-32.9M

Net Profit

$-34.7M

Gross Margin

48.5%

Operating Margin

-168.5%

Net Margin

-177.4%

YoY Growth

-56.5%

EPS

$-0.09

Financial Flow

STANDARD BIOTOOLS INC. Q3 2025 Financial Summary

STANDARD BIOTOOLS INC. reported revenue of $19.6M for Q3 2025, with a net profit of $-34.7M (-177.4% margin). Cost of goods sold was $10.1M, operating expenses totaled $42.4M.

Key Financial Metrics

Total Revenue$19.6M
Net Profit$-34.7M
Gross Margin48.5%
Operating Margin-168.5%
Report PeriodQ3 2025

STANDARD BIOTOOLS INC. Annual Revenue by Year

STANDARD BIOTOOLS INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $174.4M).

YearAnnual Revenue
2024$174.4M
2023$106.3M
2022$97.9M

Income Statement

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Revenue$28.2M$45.5M$37.2M$45.0M$46.7M$40.8M$21.8M$19.6M
YoY Growth4.3%81.3%34.5%77.3%65.7%-10.4%-41.5%-56.5%

Balance Sheet

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Assets$323.1M$777.7M$708.7M$681.5M$612.3M$579.6M$557.0M$539.6M
Liabilities$159.9M$200.4M$198.5M$192.2M$140.6M$125.0M$132.4M$140.0M
Equity$-148.1M$577.3M$510.3M$489.3M$471.7M$454.6M$424.5M$399.7M

Cash Flow

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
Operating CF$-14.1M$-62.5M$-39.0M$-27.9M$-14.1M$-30.3M$-20.7M$-22.2M